Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer
NCT00694291Phase 2Withdrawn
- Sponsor
- Fox Chase Cancer Center
- Start
- Jun 2008
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing Sorafenib with Placebo (2 arms). Primary endpoint: Median PSA Slope at 6 months. Planned start Jun 2008; status: withdrawn.
02
Drugs
sorafenib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00694291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00694291.